romidepsin

SynDRA canonical compound SYN0041694 — structure-anchored drug synonym record

Clinical phase	Launched
Approval status	Approved · Rx/OTC
Primary target(s)	CYP2B6 \| CYP2C19 \| CYP3A5 \| HDAC1 \| HDAC2 \| HDAC3 \| HDAC4 \| HDAC5 \| HDAC6 \| HDAC7 \| HDAC8 \| HDAC9
Mechanism of action	HDAC inhibitor
Indication	cutaneous T-cell lymphoma (CTCL)
Disease area	hematologic malignancy

All known targets

chromadax
istodax
FR901228
FK228
ROMIDEPSINE
ROMIDEPSINA
DEPSIPEPTIDE
Chromadax
CYCLIC (1.FWDARW.2)-DISULFIDE
FK-228
FR-901228
Istodax
N-(3-HYDROXY-7-MERCAPTO-1-OXO-4-HEPTENYL)VALYL- CYSTEINYL-2,3-DIDEHYDRO-2- AMINOBUTANOYL-,.XI.-LACTONE
NSC-630176
NSC 630176,
NSC754143
ROMIDEPSIN (FK228 ,DEPSIPEPTIDE)
Antibiotic FR 901228
HDInhib_000006
Chromadax (TN)
FK-901228
Istodax (TN)
Romidepsin (USAN)
Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide
L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide
(1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone
(1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone
(1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone
Depsipeptide
NSC 630176
CHEMBL343448
(1S,4S,7Z,10S,16E,21R)-7- ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23- tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone
CHEBI:61080
NSC630176
(1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-bis(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone
C24H36N4O6S2
Romidepsin [USAN]
CX3T89XQBK